Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte By Investing.com

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson encourages investors who have lost more than $75,000 in Humacyte to contact Him directly to discuss their options.

If you have incurred losses of more than $75,000 Humacyte: Between 10 May 2024 and 17 October 2024 and would like to discuss your legal rights, call a Faruqi & Faruqi partner Josh Wilson directly time 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, NY–(Newsfile Corp. – December 28, 2024) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”). (NASDAQ: HUMA ) and reminds investors January 17, 2025 deadline seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. has returned hundreds of millions of dollars to investors since its inception.See www.faruqilaw.com.

The complaint below alleges that the Company and its officers violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: practices, including quality assurance and microbiological testing; (2) that the FDA’s review of the BLA would be delayed while Humacyte corrected these deficiencies; and (3) that, as a result, there is a substantial risk to FDA approval of ATEV for vascular trauma; and (4) that as a result of the foregoing, Defendants’ positive statements regarding the Company’s operations, performance and prospects were materially misleading and/or lacked a reasonable basis.

On August 9, 2024, after the market closed, Humacyte issued a press release announcing that the Food and Drug Administration (“FDA”) would “require additional time to complete its review of its biologics license application (BLA) for the cell-derived tissue.” (ATEV) with the indication of vascular trauma.” In particular, it is stated in the press release that “[d]During the BLA review, the FDA conducted inspections of our manufacturing facilities and clinical sites and actively engaged in numerous discussions with us regarding our BLA submission.[.]”

On this news, the Company’s stock price fell $1.29, or 16.4%, to close at $6.62 per share on August 12, 2024, on unusually high volume.

On October 17, 2024, during market hours, the FDA issued a Form 483 related to Humacyte’s Durham, North Carolina facility, which disclosed a number of violations, including “no microbial quality assurance,” “no microbial testing,” and insufficient “quality control”.

On this news, the Company’s stock price fell $0.95, or 16.35%, to close at $4.86 per share on October 17, 2024 on unusually high volume.

A court-appointed lead plaintiff is the investor with the greatest financial interest in the relief sought by the class that is commensurate with and typical of the class members who direct and control the litigation on behalf of the putative class. Any member of the putative class may propose to the Court to act as lead plaintiff through an attorney of their choice, or may choose to do nothing and remain an absent class member. Your ability to participate in any recovery is not affected by serving as the lead plaintiff or the decision not to serve.

Faruqi & Faruqi, LLP also encourages anyone with information related to Humacyte’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.

Follow us for updates on LinkedIn, X, or Facebook (NASDAQ: ).

Advertisement of a lawyer. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP. Past results do not guarantee or predict any future outcome. We welcome the opportunity to discuss your particular case. All communications will be kept confidential.

To view the original version of this press release, visit https://www.newsfilecorp.com/release/234707